NASDAQ:INO', 'Inovio Pharmaceuticals Inc.', '');

196.80 % to Target, H.C. Wainwright Maintains ‘”Buy”’ Rating on Inovio Pharmaceuticals (NASDAQ:INO) Shares Today

December 7, 2017 - By Darrin Black

 196.80 % to Target, H.C. Wainwright Maintains ‘

Inovio Pharmaceuticals (NASDAQ:INO) Rating Reaffirmed

H.C. Wainwright now has a $13.0 target price per share on shares of Inovio Pharmaceuticals (NASDAQ:INO). The target price per share would suggest a potential upside of 196.80 % from the stock close price of Inovio Pharmaceuticals (NASDAQ:INO). This rating was disclosed to clients in a note on Friday, 6 October.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Ratings Coverage

Among 8 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals has $31 highest and $9 lowest target. $14.33’s average target is 227.17% above currents $4.38 stock price. Inovio Pharmaceuticals had 34 analyst reports since August 10, 2015 according to SRatingsIntel. The company was maintained on Wednesday, August 9 by Maxim Group. The stock of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has “Buy” rating given on Wednesday, August 9 by H.C. Wainwright. On Monday, March 14 the stock rating was maintained by Brean Capital with “Buy”. The firm has “Buy” rating given on Tuesday, November 28 by H.C. Wainwright. The firm has “Buy” rating given on Friday, June 2 by H.C. Wainwright. The stock of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) earned “Buy” rating by Stifel Nicolaus on Thursday, October 5. Citigroup initiated it with “Buy” rating and $10.0 target in Wednesday, September 6 report. H.C. Wainwright maintained Inovio Pharmaceuticals, Inc. (NASDAQ:INO) rating on Tuesday, September 12. H.C. Wainwright has “Buy” rating and $13.0 target. As per Thursday, July 27, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating given on Wednesday, September 9 by Maxim Group.

It closed at $4.38 lastly. It is down 29.01% since December 7, 2016 and is downtrending. It has underperformed by 45.71% the S&P500.

Analysts await Inovio Pharmaceuticals, Inc. (NASDAQ:INO) to report earnings on March, 21. They expect $-0.29 EPS, up 19.44 % or $0.07 from last year’s $-0.36 per share. After $-0.40 actual EPS reported by Inovio Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -27.50 % EPS growth.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company has market cap of $395.50 million. The Company’s SynCon immunotherapy design has the ability to break the immune systemÂ’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It currently has negative earnings. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus.

More recent Inovio Pharmaceuticals, Inc. (NASDAQ:INO) news were published by: which released: “Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with …” on November 27, 2017. Also published the news titled: “Why Inovio Pharmaceuticals Inc. Is Sinking Today” on November 09, 2017.‘s news article titled: “Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors” with publication date: December 06, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.